We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Bracco Diagnostics Acquires E-Z-EM

By HospiMedica staff writers
Posted on 31 Oct 2007
Bracco Diagnostics, a US based subsidiary of Bracco Imaging, S.p.A and part of the Bracco group, announced the acquisition of E-Z-EM, a recognized contrast agent manufacturer for diagnostic imaging of the GI tract. More...


E-Z-EM and Bracco Diagnostics have a longstanding association: E-Z-EM manufactures an oral imaging product for Bracco, and Bracco, as distributors, represents E-Z-EM in Italy. Bracco Diagnostics is one of the world's leading companies in the imaging agent business, while E-Z-EM is a leading manufacturer of contrast agents for gastrointestinal radiology. In addition, it is worth noting that E-Z-EM was named among the Best Small Companies in America in 2007 by Forbes magazine.

Both companies are well positioned with respected brands in the marketplace and the expected synergies from the merger will certainly enhance their standing. Bracco believes in the strong strategic fit of E-Z-EM to strengthen its core business and to consolidate its presence in the sector. In fact, the merger represent an initiative pursued by the E-Z-EM board of directors as the best alternative to increase shareholder value.

Under the terms of the agreement, Bracco will acquire all outstanding shares of E-Z-EM for US$21 per share for a total consideration of nearly $241 million. Subject to a majority vote by E-Z-EM shareholders and U.S. regulatory approval, the transaction will close sometime early in 2008, with a merger by incorporation of E-Z-EM into Bracco Diagnostics.

E-Z-EM (Lake Success, NY, USA) is a leading manufacturer of contrast agents for radiology and the developer of VoLumen, a next generation low-density barium sulfate suspension for use as an oral contrast in Multidetector CT (MDCT) and Positron Emission Tomography (PET/CT) studies. E-Z-EM is also the worldwide manufacturer and marketer of Reactive Skin Decontamination Lotion (RSDL), a broad-spectrum liquid chemical warfare agent decontaminant.

Bracco Diagnostics, Inc., (Princeton, NJ, USA) one of the world's leading companies in the imaging agent business, is a US subsidiary of Bracco Imaging S.p.A of Milan, Italy, which also markets ethical, and OTC pharmaceutical products and healthcare services in Italy, as well as advanced medical technology systems on a worldwide basis.


Related Links:
E-Z-EM
Bracco Diagnostics

Platinum Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
Electrode Solution and Skin Prep
Signaspray
Infrared Digital Thermometer
R1B1
Isolation Stretcher
IS 736
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.